Regorafenib can enhance the effect of immune checkpoint inhibitor by modulating the IFN-γ/NSDHL/SREBP1/TGF-β1 axis against HCC, and this treatment potently suppresses JAK1/2-STAT and MAPK signaling to attenuate IFNγ-induced PD-L1 expression.[33.34] Moreover, regorafenib improved survival by increasing intratumoral CXCR3 + CD8 T cell infiltration and normalizing the cancer vasculature [35]. Here, TGFB1 is linked to hepatocellular carcinoma.